<ARTICLE>                     5
<LEGEND>
This schedule  contains  summary  financial   information  extracted  from  ICN
Pharmaceuticals,  Inc.'s  September 30, 1998  Consolidated  Condensed Financial
Statements  and is qualified  in its  entirety by  reference  to such financial
statements.
</LEGEND>
<CIK>                         0000930184
<NAME>                        ICN Pharmaceuticals, Inc.
<MULTIPLIER>                                   1,000

       

                             
<PERIOD-TYPE>                    9-mos
<FISCAL-YEAR-END>                              Dec-31-1998
<PERIOD-START>                                 Jan-01-1998
<PERIOD-END>                                   Sep-30-1998

<CASH>                                         255,439
<SECURITIES>                                         0
<RECEIVABLES>                                  280,291
<ALLOWANCES>                                   (67,323)
<INVENTORY>                                    171,171
<CURRENT-ASSETS>                               707,141
<PP&E>                                         482,818
<DEPRECIATION>                                 (67,349)
<TOTAL-ASSETS>                               1,560,418
<CURRENT-LIABILITIES>                          206,446
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          1
<COMMON>                                           735
<OTHER-SE>                                     714,322
<TOTAL-LIABILITY-AND-EQUITY>                 1,560,418
<SALES>                                        610,047
<TOTAL-REVENUES>                               636,730
<CGS>                                          278,585
<TOTAL-COSTS>                                  278,585
<OTHER-EXPENSES>                                16,640
<LOSS-PROVISION>                               205,530
<INTEREST-EXPENSE>                              24,698
<INCOME-PRETAX>                               (168,129)
<INCOME-TAX>                                     5,147
<INCOME-CONTINUING>                           (128,773)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (128,773)
<EPS-PRIMARY>                                    (1.77)
<EPS-DILUTED>                                    (1.77)